JP2018531891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531891A5 JP2018531891A5 JP2018506976A JP2018506976A JP2018531891A5 JP 2018531891 A5 JP2018531891 A5 JP 2018531891A5 JP 2018506976 A JP2018506976 A JP 2018506976A JP 2018506976 A JP2018506976 A JP 2018506976A JP 2018531891 A5 JP2018531891 A5 JP 2018531891A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- bet
- bcl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203128P | 2015-08-10 | 2015-08-10 | |
| US62/203,128 | 2015-08-10 | ||
| PCT/US2016/046318 WO2017027571A1 (en) | 2015-08-10 | 2016-08-10 | Mechanism of resistance to bet bromodomain inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531891A JP2018531891A (ja) | 2018-11-01 |
| JP2018531891A5 true JP2018531891A5 (enExample) | 2019-09-19 |
Family
ID=57984534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506976A Pending JP2018531891A (ja) | 2015-08-10 | 2016-08-10 | Ｂｅｔブロモドメインインヒビターに対する抵抗性の機構 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11666580B2 (enExample) |
| EP (2) | EP3334725B1 (enExample) |
| JP (1) | JP2018531891A (enExample) |
| KR (1) | KR20180035905A (enExample) |
| CN (1) | CN108137550A (enExample) |
| AU (2) | AU2016304856B8 (enExample) |
| BR (1) | BR112018002550A2 (enExample) |
| CA (1) | CA2995374A1 (enExample) |
| CL (1) | CL2018000377A1 (enExample) |
| HK (1) | HK1254201A1 (enExample) |
| IL (1) | IL257386A (enExample) |
| MX (1) | MX2018001737A (enExample) |
| PE (1) | PE20181088A1 (enExample) |
| RU (1) | RU2018108165A (enExample) |
| WO (1) | WO2017027571A1 (enExample) |
| ZA (1) | ZA201800969B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
| GB201704536D0 (en) * | 2017-03-22 | 2017-05-03 | Univ Malta | Method |
| WO2019032810A2 (en) * | 2017-08-09 | 2019-02-14 | Mayo Foundation For Medical Education And Research | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BETA-INHIBITORY RESISTANT CANCERS |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
| US12290521B2 (en) | 2018-07-25 | 2025-05-06 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating BET inhibitor-resistant cancers |
| WO2020132259A1 (en) * | 2018-12-21 | 2020-06-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) |
| PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| JPWO2023157891A1 (enExample) * | 2022-02-16 | 2023-08-24 | ||
| CN114617878A (zh) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Ck2抑制剂在制备抗衰药物中的应用 |
| CN115894678B (zh) * | 2022-07-15 | 2023-10-20 | 新疆赛尔托马斯生物科技有限公司 | 一种干细胞细胞因子的制备方法及其在制备药品中的用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA103867A (en) | 1907-02-01 | 1907-03-05 | Charles M. Thrasher | Nut lock |
| CA120184A (en) | 1908-09-08 | 1909-08-24 | George Albert Thornhill | Bottle labelling machine |
| CA168504A (en) | 1915-01-09 | 1916-03-28 | Carl Lorentz Nilson | Locomotive |
| WO1998047920A1 (en) | 1997-04-18 | 1998-10-29 | Chugai Research Institute For Molecular Medicine, Inc. | Transcriptional regulator |
| EP1077219A4 (en) | 1998-04-30 | 2005-02-23 | Chugai Pharmaceutical Co Ltd | Transcriptional, regulatory factor |
| US20120028912A1 (en) | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| US6607916B2 (en) | 2001-02-08 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Casein kinase 2-alpha expression |
| US8522267B2 (en) | 2002-03-08 | 2013-08-27 | Caption Colorado Llc | Method and apparatus for control of closed captioning |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| WO2006065724A2 (en) | 2004-12-14 | 2006-06-22 | Regents Of The University Of Minnesota | Casein kinase 2 antisense therapy |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| WO2008060695A2 (en) | 2006-05-22 | 2008-05-22 | The Trustees Of The University Of Pennsylvania | Antiviral inhibition of casein kinase ii |
| ES2414205T3 (es) | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| WO2009117769A1 (en) | 2008-03-25 | 2009-10-01 | Newcastle Innovation Limited | Inhibition of c-kit cancers |
| JP2012523458A (ja) | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
| US9307184B2 (en) | 2009-07-31 | 2016-04-05 | Echostar Technologies L.L.C. | Multi-user recording allocation |
| US8865901B2 (en) | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| US8862173B2 (en) | 2009-12-10 | 2014-10-14 | Motorola Solutions, Inc. | Method for selecting media for delivery to users at an incident |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| RU2593231C2 (ru) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| EP2861255B1 (en) * | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| DE102012212436B4 (de) | 2012-07-16 | 2022-07-14 | Coretronic Corporation | Lichtmodul für eine Projektionsvorrichtung und Verfahren zur Generierung des Blauanteils in einem Lichtmodul für eine Projektionsvorrichtung |
| US20150272970A1 (en) | 2012-09-07 | 2015-10-01 | Carlos Cordon-Cardo | Targeting chemotherapy agent resistance in cancer |
| US20140296218A1 (en) | 2012-10-25 | 2014-10-02 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| US11446309B2 (en) * | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| JP2016538310A (ja) | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| AU2015206194A1 (en) * | 2014-01-20 | 2016-07-28 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
-
2016
- 2016-08-10 BR BR112018002550-0A patent/BR112018002550A2/en not_active IP Right Cessation
- 2016-08-10 JP JP2018506976A patent/JP2018531891A/ja active Pending
- 2016-08-10 CN CN201680058347.9A patent/CN108137550A/zh active Pending
- 2016-08-10 EP EP16835823.2A patent/EP3334725B1/en active Active
- 2016-08-10 AU AU2016304856A patent/AU2016304856B8/en active Active
- 2016-08-10 RU RU2018108165A patent/RU2018108165A/ru unknown
- 2016-08-10 MX MX2018001737A patent/MX2018001737A/es unknown
- 2016-08-10 KR KR1020187006573A patent/KR20180035905A/ko not_active Withdrawn
- 2016-08-10 HK HK18113341.9A patent/HK1254201A1/zh unknown
- 2016-08-10 EP EP25171764.1A patent/EP4585273A3/en active Pending
- 2016-08-10 WO PCT/US2016/046318 patent/WO2017027571A1/en not_active Ceased
- 2016-08-10 US US15/751,914 patent/US11666580B2/en active Active
- 2016-08-10 PE PE2018000226A patent/PE20181088A1/es unknown
- 2016-08-10 CA CA2995374A patent/CA2995374A1/en not_active Abandoned
-
2018
- 2018-02-07 IL IL257386A patent/IL257386A/en unknown
- 2018-02-09 CL CL2018000377A patent/CL2018000377A1/es unknown
- 2018-02-13 ZA ZA2018/00969A patent/ZA201800969B/en unknown
-
2021
- 2021-04-20 AU AU2021202388A patent/AU2021202388A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018108165A (ru) | Механизм устойчивости к ингибиторам бромодомена (bet) | |
| Hu et al. | Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer | |
| Wong et al. | Saikosaponin‐d Enhances the Anticancer Potency of TNF‐α via Overcoming Its Undesirable Response of Activating NF‐Kappa B Signalling in Cancer Cells | |
| Hong et al. | Redifferentiation of radioiodine refractory differentiated thyroid cancer for reapplication of I-131 therapy | |
| CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
| BR112016022785A8 (pt) | composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| Zhang et al. | The renewed battle against RAS-mutant cancers | |
| Kuo et al. | Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo | |
| Hassan et al. | Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: significance for melanoma treatment | |
| Negi et al. | Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells | |
| JP2015511226A5 (enExample) | ||
| BR112015002706A8 (pt) | Niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| Wang et al. | Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells | |
| Wilkinson et al. | Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis | |
| Burmi et al. | Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells | |
| WO2016110806A3 (en) | Dosage regimen for madcam antagonists | |
| Tang et al. | Gambogic acid inhibits the growth of ovarian cancer tumors by regulating p65 activity | |
| Ghoochani et al. | Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis | |
| Ninomiya et al. | Arsenite induces premature senescence via p53/p21 pathway as a result of DNA damage in human malignant glioblastoma cells | |
| Wang et al. | Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer | |
| JP2015508903A5 (enExample) | ||
| Ito et al. | The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo | |
| JP2016526021A5 (enExample) | ||
| Jang et al. | BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1 |